angioplasty

La angioplastia “ad hoc” durante el TAVI no impacta en su seguridad ni en resultados a largo plazo

“Ad Hoc” PCI during TAVR: No Impact on Safety or Long Term Outcomes

According to a recent study published in&nbsp;Circulation Cardiovascular Interventions, screening for coronary artery disease&nbsp;(CAD) with an invasive coronary angiography&nbsp; (as part of the protocol prior TAVR) &nbsp;and performing PCI and TAVR&nbsp;in the same session, has no impact on periprocedural safety or on long term outcomes. Study outcomes offer new hope, especially as regards using TAVR<a href="https://solaci.org/en/2017/09/06/ad-hoc-pci-during-tavr-no-impact-on-safety-or-long-term-outcomes/" title="Read more" >...</a>

Los stent autoxpandibles son superiores a los de balón expandibles en el territorio ilíaco

Self-Expanding Stents Are Superior to Balloon-Expandable Stents in the Iliac Arteries

Courtesy of Dr. Carlos&nbsp;Fava. Severe atherosclerotic disease in&nbsp;iliac arteries is experienced by 15% of all men and 5% of all women. TAC&nbsp;II recommends&nbsp;angioplasty for type-A, -B, and -C lesions. As regards stent type, self-expanding stent (SE, more elasticity) vs. balloon-expandable stent (SB, more radial strength), Reekers indicates superior target lesion&nbsp;revascularization (TLR) with SE. However, there<a href="https://solaci.org/en/2017/09/05/self-expanding-stents-are-superior-to-balloon-expandable-stents-in-the-iliac-arteries/" title="Read more" >...</a>

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the &nbsp;New England Journal of Medicine&nbsp;along with their presentation at ESC 2017. The traditional triple anti-thrombotic scheme with dual antiplatelet therapy &nbsp;and&nbsp;warfarin for patients with atrial fibrillation undergoing coronary angioplasty&nbsp;seems to have been left behind. &nbsp; This new study showed that the combination of dabigatran with a P2Y12<a href="https://solaci.org/en/2017/09/04/re-dual-pci-anti-thrombotic-management-in-patients-with-atrial-fibrillation-and-pci/" title="Read more" >...</a>

Sorpresivo hallazgo en diabetes y permeabilidad de los bypass

Striking Finding on Diabetes and Bypass Graft Patency

The higher rate of restenosis in the diabetic&nbsp;population is historic and has been reproduced in all studies and with all kinds of stents, but it was only after the FREEDOM trial when we found out about the higher infarction rate with&nbsp;PCI&nbsp;compared to surgery. This is why 50% of patients undergoing&nbsp;CABG&nbsp;are diabetic. Apart from the above<a href="https://solaci.org/en/2017/09/01/striking-finding-on-diabetes-and-bypass-graft-patency/" title="Read more" >...</a>

¿Debemos comenzar a utilizar IVUS en las CTO?

Should We Begin to Use IVUS in CTO?

Courtesy of Dr. Carlos&nbsp;Fava. Currently,&nbsp;chronic total occlusions&nbsp;(CTO)&nbsp;are one of the obstacles that&nbsp;coronary angioplasties must overcome, particularly with the development of&nbsp;drug-eluting stents (DES)&nbsp;and new devices and strategies for these challenging lesions. However, there is little information on the safety, efficacy, and real clinical benefit of implanting stents of over 60&nbsp;mm (known as full metal jackets, FMJ).<a href="https://solaci.org/en/2017/08/28/should-we-begin-to-use-ivus-in-cto/" title="Read more" >...</a>

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

2 Year Outcomes of Lutonix Drug Coated Balloon in Superficial Femoral Arteries

&nbsp; There are plenty of clinical studies assessing the use of angioplasty&nbsp;for en la&nbsp;peripheral artery disease&nbsp;with restenosis rates as high as 40% and 60% at 6 and 12 months. Drug coated balloons have significantly raised primary patency, but they have mostly been tested in short lesions with mild calcification and no total occlusions. &nbsp; This<a href="https://solaci.org/en/2017/08/23/2-year-outcomes-of-lutonix-drug-coated-balloon-in-superficial-femoral-arteries/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

Bleeding and Mortality in Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR)&nbsp;is much less invasive than surgical replacement. This is associated with a substantial reduction in&nbsp;bleeding events (up to 60% less). However, clinically relevant bleeding is still present in one every four patients who undergo TAVR, which is associated with morbidity and mortality. &nbsp; Cases of bleeding are not uniform: they may<a href="https://solaci.org/en/2017/08/22/bleeding-and-mortality-in-transcatheter-aortic-valve-replacement/" title="Read more" >...</a>

Trombosis y riesgo de sangrado

Risk of Thrombosis and Bleeding with Peripheral Artery Disease and Concomitants

Peripheral artery disease (PAD) is no longer a systemic manifestation of atherosclerosis. In fact, 2 in 3 people with PAD have concomitant heart disease, and 1 in 3 people has concomitant PAD. &nbsp; To understand the real dimension of this problem, we should know that PAD patients have 60% more risk of acute myocardial infarction<a href="https://solaci.org/en/2017/08/22/risk-of-thrombosis-and-bleeding-with-peripheral-artery-disease-and-concomitants/" title="Read more" >...</a>

presentaciones ProEducar

See All ProEducar “José Gabay” Course (Eighth Edition) Presentations

We are deeply thankful to all interventional physicians who, motivated by their great scientific and educational vocation, presented their works at the “José Gabay” Course and actively collaborated in training and providing updated concepts for the next generations of interventional cardiologists. Read and/or download the presentations below: &nbsp; Module&nbsp;I: Fundamentals and Basic Elements. Álvarez, José.<a href="https://solaci.org/en/2017/08/22/see-all-proeducar-jose-gabay-course-eighth-edition-presentations/" title="Read more" >...</a>

La revascularización incompleta se asocia a mortalidad en el TAVI

Incomplete Revascularization Is Associated with Mortality in TAVR

Courtesy of Dr. Carlos Fava. TAVR&nbsp;has proven to be beneficial for inoperable and high-risk patients, as well as for intermediate-risk patients. However, while many comorbidities have been analyzed, the presence, severity, and impact of&nbsp;coronary disease&nbsp;has not been well studied yet. This study analyzed 1270&nbsp;patients who underwent TAVR. They presented &gt;50% lesions in a major epicardial<a href="https://solaci.org/en/2017/08/15/incomplete-revascularization-is-associated-with-mortality-in-tavr/" title="Read more" >...</a>

Top